PMID- 15767030
OWN - NLM
STAT- MEDLINE
DCOM- 20050512
LR  - 20050315
IS  - 0300-483X (Print)
IS  - 0300-483X (Linking)
VI  - 209
IP  - 2
DP  - 2005 Apr 15
TI  - Virus reactivation and intravenous immunoglobulin (IVIG) therapy of drug-induced 
      hypersensitivity syndrome.
PG  - 165-7
AB  - Drug-induced hypersensitivity syndrome (DIHS) is a severe multi-organ system 
      reaction caused by specific drugs. Many reports have revealed that human 
      herpesvirus 6 (HHV-6) reactivation contributes to the development of DIHS. In 
      addition, recent articles have shown that reactivation of other herpesviruses 
      such as human herpesvirus 7 (HHV-7), Epstein-Barr virus (EBV), cytomegalovirus 
      (CMV) might be also implicated in the development of DIHS. These observations 
      suggest that not only HHV-6 but also other herpesvirses might reactivate from the 
      latency and play an important role in the appearance of clinical manifestations 
      of DIHS. Several patients with DIHS were treated with intravenous immunoglobulin 
      (IVIG) in addition to systemic corticosteroids. The results have been encouraging 
      although virus reactivation could not be suppressed. Although the pathomechanism 
      of IVIG treatment in patients with DIHS remains unknown, the therapeutic effects 
      of IVIG could be dependent, in part, on functional capabilities of anti-virus IgG 
      contained in IVIG.
FAU - Kano, Yoko
AU  - Kano Y
AD  - Department of Dermatology, Kyorin University School of Medicine, 6-20-2 Shinkawa 
      Mitaka, Tokyo 181-8611, Japan. kano@kyorin-u.ac.jp
FAU - Inaoka, Miyuki
AU  - Inaoka M
FAU - Sakuma, Keiichi
AU  - Sakuma K
FAU - Shiohara, Tetsuo
AU  - Shiohara T
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Ireland
TA  - Toxicology
JT  - Toxicology
JID - 0361055
RN  - 0 (Immunoglobulins, Intravenous)
SB  - IM
MH  - Drug Hypersensitivity/*therapy/*virology
MH  - Herpesvirus 6, Human/immunology
MH  - Herpesvirus 7, Human/immunology
MH  - Humans
MH  - Immunoglobulins, Intravenous/*therapeutic use
MH  - Roseolovirus Infections/complications/immunology
MH  - Virus Diseases/*complications/immunology
RF  - 9
EDAT- 2005/03/16 09:00
MHDA- 2005/05/13 09:00
CRDT- 2005/03/16 09:00
PHST- 2005/03/16 09:00 [pubmed]
PHST- 2005/05/13 09:00 [medline]
PHST- 2005/03/16 09:00 [entrez]
AID - S0300-483X(04)00713-9 [pii]
AID - 10.1016/j.tox.2004.12.013 [doi]
PST - ppublish
SO  - Toxicology. 2005 Apr 15;209(2):165-7. doi: 10.1016/j.tox.2004.12.013.